N-((5-chloro-8-hydroxyquinolin-7-yl)(pyridin-3-yl)methyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-((5-chloro-8-hydroxyquinolin-7-yl)(pyridin-3-yl)methyl)acetamide
• 英文别名: N-[(5-chloro-8-hydroxyquinolin-7-yl)-pyridin-3-ylmethyl]acetamide
• 化学式: C₁₇H₁₄ClN₃O₂
• 分子量: 327.77
• InChiKey: PFAGOWWNQYNZCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-吡啶甲醛 、 乙酰胺 、 5-氯-8-羟基喹啉 反应 0.5h， 以27%的产率得到N-((5-chloro-8-hydroxyquinolin-7-yl)(pyridin-3-yl)methyl)acetamide
  参考文献：
  名称：

  WO2008/14602

  摘要：

  公开号：

文献信息

• QUINOLINE DERIVATIVES
  申请人：Envivo Pharmaceuticals, Inc.

  公开号：EP2079699A1

  公开（公告）日：2009-07-22
• [EN] QUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOLINE
  申请人：CHRONOGEN INC

  公开号：WO2008014602A1

  公开（公告）日：2008-02-07

  [EN] The invention relates to new quinoline derivatives which are active CLK-1 inhibitors. More specifically, the CLK-1 inhibitors of the invention are compounds of formula (A). The invention also relates to pharmaceutical compositions comprising such compounds and to methods for the prophylaxis and/or treatment of disorders or their associated symptoms for which the inhibition of CLK-1 is beneficial.
  [FR] L'invention concerne de nouveaux dérivés de quinoline constituant des inhibiteurs actifs de CLK-1. Les inhibiteurs de CLK-1 de l'invention sont, plus spécifiquement, des composés représentés par la formule (A). L'invention concerne également des compositions pharmaceutiques contenant lesdits composés et des méthodes prophylactiques et/ou thérapeutiques de troubles ou des symptômes associés dans lesquels l'inhibition de CLK-1 est bénéfique.
• [EN] SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE GRP78 ET LEURS UTILISATIONS
  申请人：[en]THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：WO2022169834A2

  公开（公告）日：2022-08-11

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules as defined within Formula I (as defined herein) which function as inhibitors of glucose-regulated protein 78 (GRP78) within cancer cells and/or immune cells, and which function as effective therapeutic agents for treating, ameliorating, and preventing various forms of cancer (e.g., pancreatic cancer), viral infections (e.g. SARS-CoV-2), and inflammatory diseases. In addition, this invention also relates to a new class of PROTACs having Formulas II, III and IV (as defined herein) which function as degraders of GRP78 within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds of Formulas I, II, III, or IV are also within the scope of the present invention.
• WO2008/14602
  申请人：——

  公开号：——

  公开（公告）日：——